Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine. The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability. Valneva’s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO®) and the second (DUKORAL®) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant). Valneva is incorporated in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Scotland and Sweden with approximately 400 employees.
Type
Public
HQ
Lyon, FR
Employees
17,686 (est)
Valneva is headquartered in Lyon, FR

Key People at Valneva

Thomas Lingelbach

Thomas Lingelbach

President & Chief Executive Officer

Valneva Locations

Lyon, FR

Valneva Metrics

Valneva Summary

Market capitalization

€1.01 B

Closing share price

€5.58
Valneva's latest market capitalization is €1.01 B.

Valneva Market Value History

Valneva Company Life